TABLE 1.

Encapsulation parameters of the various liposome formulations as a function of the preparation procedure and lipid matrix composition^a

Liposomesb	MLVc		FATMLVd		LUVETe
	DCf	ECg	DC	EC	DC	EC
MC-Chol-DP	8.1 ± 2.4	5.8 ± 1.6	22.7 ± 3.8	16.3 ± 2.7	21.8 ± 2.6	15.7 ± 1.9
MC-Chol-PS	9.2 ± 2.7	6.5 ± 2.1	28.9 ± 4.3	20.8 ± 3.1	29.2 ± 5.2	21.0 ± 3.7
MC-Chol-PE	5.9 ± 1.8	4.3 ± 1.1	12.8 ± 3.5	9.2 ± 2.5	12.4 ± 3.1	8.9 ± 2.2
MC-Chol-PA	5.1 ± 2.9	3.6 ± 2.2	10.1 ± 2.9	7.1 ± 1.8	10.2 ± 3.3	7.3 ± 2.4

^aEach value is the average of five different experiments ± standard deviation. 

^bMC, 1,2-dimyristoyl-sn-glycero-phosphocholine monohydrate; Chol, cholesterol; DP, dihexadecyl hydrogen phosphate; PS, dipalmitoyl-dl-α-phosphatidyl-l-serine; PE, 1,2-dipalmitoyl-sn-glycero-phosphoethanolamine; PA, 1,2-dipalmitoyl-sn-glycero-phosphatidic acid sodium salt. 

^cMultilamellar vesicles (MLV) prepared by lipid film dispersion in isotonic phosphate buffer. 

^dFreeze-and-thaw MLV (FATMLV). 

^eLarge unilamellar vesicles (LUVET) obtained from FATMLV by an extrusion technique through polycarbonate membranes. 

^fDrug content (DC) as percentage of drug entrapped within liposomes. 

^gEncapsulation capacity (EC) as microliters of aqueous solution entrapped per micromole of lipids.